Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Rodrigo Dienstmann, Jordi Rodón, Aleix Prat, et al.
Annals of Oncology (2013) Vol. 25, Iss. 3, pp. 552-563
Open Access | Times Cited: 342

Showing 26-50 of 342 citing articles:

Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
Marsel Khabibov, Айрат Гарифуллин, Yanis Boumber, et al.
International Journal of Oncology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 77
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 40
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 2
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
J.C. Soria, Filippo de Braud, Rastilav Bahleda, et al.
Annals of Oncology (2014) Vol. 25, Iss. 11, pp. 2244-2251
Open Access | Times Cited: 166
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Daniel Morgensztern, Meghan Campo, Suzanne E. Dahlberg, et al.
Journal of Thoracic Oncology (2015) Vol. 10, Iss. 1, pp. S1-S63
Open Access | Times Cited: 131
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Teresa Helsten, Maria Schwaederlé, Razelle Kurzrock
Cancer and Metastasis Reviews (2015) Vol. 34, Iss. 3, pp. 479-496
Open Access | Times Cited: 121
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
Pharmacological Research (2019) Vol. 151, pp. 104567-104567
Closed Access | Times Cited: 116
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Mei Zhou, Hong Yang, R. Marc Learned, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 115
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 4, pp. 764-774
Open Access | Times Cited: 105
FGFR Signaling as a Target for Lung Cancer Therapy
Arpita Desai, Alex A. Adjei
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 1, pp. 9-20
Open Access | Times Cited: 101
Fibroblast Growth Factor Receptor Functions in Glioblastoma
Ana Jimenez‐Pascual, Florian A. Siebzehnrübl
Cells (2019) Vol. 8, Iss. 7, pp. 715-715
Open Access | Times Cited: 100
Targeting FGFR pathway in breast cancer
Jose Manuel Perez‐García, Eva Muñoz‐Couselo, Jesús Soberino, et al.
The Breast (2017) Vol. 37, pp. 126-133
Open Access | Times Cited: 97
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
Frank Hilberg, Ulrike Tontsch-Grunt, Anke Baum, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 364, Iss. 3, pp. 494-503
Open Access | Times Cited: 91
Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets
Franz Enkner, Bettina Pichlhöfer, Alexandru Zaharie, et al.
Pathology & Oncology Research (2016) Vol. 23, Iss. 3, pp. 551-564
Open Access | Times Cited: 89
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher, et al.
British Journal of Cancer (2017) Vol. 117, Iss. 11, pp. 1592-1599
Open Access | Times Cited: 88
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
Sylvia Grünewald, Oliver Politz, Sebastian Bender, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 5, pp. 1346-1357
Open Access | Times Cited: 85
The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
Maria Francesca Santolla, Marcello Maggiolini
Cancers (2020) Vol. 12, Iss. 10, pp. 3029-3029
Open Access | Times Cited: 82
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies
Liwei Lang, Yong Teng
Cells (2019) Vol. 8, Iss. 1, pp. 31-31
Open Access | Times Cited: 80
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6549-6569
Closed Access | Times Cited: 9
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences
Kai Wang, Adrienne Johnson, Siraj M. Ali, et al.
The Oncologist (2015) Vol. 20, Iss. 10, pp. 1132-1139
Open Access | Times Cited: 90
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors
Cinta Hierro, Jordi Rodón, Josep Tabernero
Seminars in Oncology (2015) Vol. 42, Iss. 6, pp. 801-819
Closed Access | Times Cited: 87
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Terence Hall, Yi Yu, Sudharshan Eathiraj, et al.
PLoS ONE (2016) Vol. 11, Iss. 9, pp. e0162594-e0162594
Open Access | Times Cited: 84
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis
Roberto Ronca, Arianna Giacomini, Marco Rusnati, et al.
Expert Opinion on Therapeutic Targets (2015) Vol. 19, Iss. 10, pp. 1361-1377
Closed Access | Times Cited: 82
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
Tomohiro Nishina, Shunji Takahashi, Ryota Iwasawa, et al.
Investigational New Drugs (2017) Vol. 36, Iss. 3, pp. 424-434
Closed Access | Times Cited: 74

Scroll to top